Results 1 to 10 of about 17,755 (216)

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan [PDF]

Journal of Pharmaceutical Policy and Practice
Background Biosimilars present a significant opportunity for cost savings. However, the uptake of biosimilars has been inconsistent across different regions and drugs, highlighting the need for effective policy interventions.
Hiroaki Mamiya, Toshiki Fukasawa, Koji Kawakami   +2 more
doaj   +2 more sources

Biosimilars [PDF]

Journal of the European Academy of Dermatology and Venereology, 2018
Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
  +13 more sources

Biosimilars [PDF]

Lupus, 2020
Biological therapies have widened the therapeutic armamentarium for immune-mediated inflammatory diseases, providing in many cases a broad range of treatment options with different mechanisms of action. The widespread use of biological agents in systemic lupus erythematosus is currently limited to belimumab and rituximab, although results of promising
Christopher J Edwards, Salvatore Bellinvia   +1 more
  +6 more sources

Biosimilars in rheumatoid arthritis in 2022 – data from the Romanian Registry of Rheumatic Diseases [PDF]

Romanian Journal of Rheumatology, 2023
Objective. The study aimed at determining whether RA patients starting or stopping biosimilars differ in any regard from those starting or stopping originals. Methods.
Horatiu Popoviciu, Florentin Vreju, Claudiu C. Popescu, Corina Mogosan, Elena Rezus, Simona Rednic, Andra Balanescu, Razvan Adrian Ionescu, Catalin Codreanu   +8 more
doaj   +1 more source

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Biosimilars can improve patient access to biological medicines. Although biosimilars have been shown to be equally effective and safe, some patients remain reluctant to transition to biosimilars.
Chiara Gasteiger, Norina Gasteiger, Keith J. Petrie   +2 more
doaj   +1 more source

Biosimilar insulins in international and domestic practice of pharmacist

Фармацевтичний журнал, 2022
In Ukraine, people with diabetes receive insulin, including insulin biosimilars in pharmacies, so pharmacists should increase their knowledge about biosimilar because they become more available in the coming years. The aim of the work was to summarize
I. O. Vlasenko, I. V. Nizhenkovska
doaj   +1 more source

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2020
Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated.
Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen   +9 more
doaj   +1 more source

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

Therapeutic Advances in Gastroenterology, 2021
Background: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients.
Karoline Soares Garcia, Bianca Pocopetz Facas, Marta Brenner Machado, Fábio Vieira Teixeira, Luisa Avedano, Sanna Lönnfors, Rogério Saad Hossne, Laurent Peyrin-Biroulet, Natália Sousa Freitas Queiroz   +8 more
doaj   +1 more source

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey

Frontiers in Pharmacology, 2022
Objective: With increasing numbers of biosimilars entering the market or in the approval pipeline in China, understanding the current awareness and attitudes of biosimilars still remains the first step to promote uptake.
Yang Hu, Yang Hu, Yang Hu, Yang Hu, Zaiwei Song, Zaiwei Song, Zaiwei Song, Dan Jiang, Dan Jiang, Dan Jiang, Dan Jiang, Lin Zhuo, Yinchu Cheng, Yinchu Cheng, Yinchu Cheng, Rongsheng Zhao, Rongsheng Zhao, Rongsheng Zhao   +17 more
doaj   +1 more source